Actelion Launches 500-Patient Phase III Trial For Next-Generation PAH Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Taking the Actelion-1 compound to market would give Swiss firm an edge in PAH battle with Gilead.
You may also be interested in...
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.
Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip
Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.